These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7438695)

  • 1. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydralazine kinetics in hypertensive patients after intravenous administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):736-42. PubMed ID: 7438689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.
    Reece PA; Stafford I; Prager RH; Walker GJ; Zacest R
    J Pharm Sci; 1985 Feb; 74(2):193-6. PubMed ID: 3989691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
    Shen DD; Hosler JP; Schroder RL; Azarnoff DL
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone.
    Talseth T; Haegele KD; McNay JL; Skrdlant HB; Clementi WA; Shepherd AM
    J Pharmacol Exp Ther; 1979 Dec; 211(3):509-13. PubMed ID: 512915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.
    Shepherd AM; Ludden TM; Haegele KD; Talseth T; McNay JL
    Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):129-44. PubMed ID: 515498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intravenous dose on hydralazine kinetics after administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1983 Aug; 34(2):148-52. PubMed ID: 6872407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of hydralazine elimination.
    Talseth T
    Clin Pharmacol Ther; 1977 Jun; 21(6):715-20. PubMed ID: 862310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic acetylation of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1980 Sep; 28(3):350-5. PubMed ID: 7408395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.
    Facchini V; Timbrell JA
    Br J Clin Pharmacol; 1981 Apr; 11(4):345-51. PubMed ID: 7259927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of oral hydralazine in chronic heart failure.
    Hanson A; Johansson BW; Wernersson B; Wåhlander LA
    Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and quantitation of hydrazine in the urine of patients treated with hydralazine.
    Timbrell JA; Harland SJ
    Clin Pharmacol Ther; 1979 Jul; 26(1):81-8. PubMed ID: 445966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1983; 25(4):553-6. PubMed ID: 6653651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat.
    Iwaki M; Ogiso T; Ito Y
    J Pharm Sci; 1989 Oct; 78(10):867-73. PubMed ID: 2600796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.